O4 - Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
Saved in:
| Title: | O4 - Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC). |
|---|---|
| Authors: | Powles, T., Motzer, R.J., Escudier, B., Heng, D.Y.C., Scheffold, C., Clary, D.O., Choueiri, T.K. |
| Source: | European Urology Supplements. Dec2016, Vol. 15 Issue 13, pe1546-e1547. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 15699056 |
|---|---|
| DOI: | 10.1016/S1569-9056(16)30377-3 |
